Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ozanimod
Drug ID BADD_D02580
Description Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.[L12573,L12582] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting.[A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Indications and Usage Ozanimod is indicated for adults in the treatment of relapsing forms of MS, which may include relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive MS.[L12582]
Marketing Status approved; investigational
ATC Code L04AA38
DrugBank ID DB12612
KEGG ID D10968
MeSH ID C000607776
PubChem ID 52938427
TTD Drug ID D07EDB
NDC Product Code Not Available
UNII Z80293URPV
Synonyms ozanimod | RPC1063
Chemical Information
Molecular Formula C23H24N4O3
CAS Registry Number 1306760-87-1
SMILES CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diabetes mellitus05.06.01.001; 14.06.01.0010.000723%-
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.0040.000241%-
Diplopia06.02.06.002; 17.17.01.0050.001640%-
Discomfort08.01.08.0030.001061%-
Disturbance in attention17.03.03.001; 19.21.02.0020.001302%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.042050%
Dizziness postural02.11.04.008; 17.02.05.004; 24.06.02.0080.001230%-
Drug ineffective08.06.01.0060.057409%-
Dry mouth07.06.01.0020.002459%
Dry throat07.06.01.005; 22.12.03.0050.000820%-
Dysarthria17.02.08.001; 19.19.03.0010.001640%
Dyspepsia07.01.02.0010.002532%
Dyspnoea02.11.05.003; 22.02.01.0040.016540%
Emotional disorder19.04.02.0050.001760%-
Extrasystoles02.03.02.0030.000651%-
Eye disorder06.08.03.0010.001881%-
Eye pain06.08.03.0020.002773%
Faeces discoloured07.01.03.0020.001230%-
Fatigue08.01.01.0020.072261%
Feeling abnormal08.01.09.0140.015889%-
Feeling cold08.01.09.0080.000820%-
Feeling jittery08.01.09.0160.001640%-
Flatulence07.01.04.0020.002459%
Frequent bowel movements07.02.04.0020.001061%-
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.012610%
Gallbladder disorder09.03.02.0010.000772%-
Gastrooesophageal reflux disease07.02.02.0030.001760%
Gastrointestinal disorder07.11.01.0010.004292%-
Gastrointestinal pain07.01.05.0050.000530%
Gingival bleeding07.09.07.001; 24.07.02.0100.000820%-
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages